Wedbush Reaffirms Outperform Rating for MannKind (NASDAQ:MNKD)
MannKind (NASDAQ:MNKD – Get Free Report)‘s stock had its “outperform” rating restated by research analysts at Wedbush in a note issued to investors on Thursday,RTT News reports. They presently have a $11.00 price target on the biopharmaceutical company’s stock. Wedbush’s price target indicates a potential upside of 105.99% from the stock’s current price. Several other […]
MannKind (NASDAQ:MNKD – Get Free Report)‘s stock had its “outperform” rating restated by research analysts at Wedbush in a note issued to investors on Thursday,RTT News reports. They presently have a $11.00 price target on the biopharmaceutical company’s stock. Wedbush’s price target indicates a potential upside of 105.99% from the stock’s current price. Several other […]
